LARS1 is a Prognostic Biomarker and Exhibits a Correlation with Immune Infiltrates in Hepatocellular Carcinoma
DOI: https://doi.org/10.2147/ijgm.s457577
IF: 2.145
2024-05-18
International Journal of General Medicine
Abstract:Longfei Fan, 1 Zhongqiang Qin, 1 Di Wu, 1 Yunchuan Yang, 2 Yigang Zhang, 2 Bo Xie, 1 Jingyu Qian, 1 Jianzhu Wei, 1 Zhaoying Wang, 1 Peipei Yang, 1 Zhen Qian, 1 Mu Yuan, 1 Ziyi Zhu, 1 Yulin Tan, 1 Yi Tan 2 1 Department of Interventional Radiology, The First Affiliated Hospital of Bengbu Medical University, Bengbu, 233000, People's Republic of China; 2 Department of Hepatobiliary Surgery, The First Affiliated Hospital of Bengbu Medical University, Bengbu, 233000, People's Republic of China Correspondence: Yi Tan, Email Purpose: To study the relationship between LARS1 expression and immune infiltration and prognosis in hepatocellular carcinoma (HCC). Patients and Methods: The clinical characteristics together with LARS1 expression levels were obtained from the TCGA database. Immunohistochemistry confirmed LARS1 expression levels in paraneoplastic and tumor tissues. To investigate LARS1-related downstream molecules, a network of protein-protein interactions (PPIs) and the Gene Ontology (GO)/Kyoto Encyclopedia of Genes and Genomes (KEGG) were built. Furthermore, gene set enrichment analysis (GSEA) was used to analyze the pathways associated with LARS1 expression, whereas Single-sample GSEA (ssGSEA) was applied to perform an association study between immune infiltration and LARS1 gene expression. The TISCH Database and the TISIDB database were used to compare the difference of LARS1 expression in hepatocellular carcinoma and immunomodulators. Results: In comparison to that in normal tissues, the LARS1 expression level was elevated in tumor tissues. LARS1 expression exhibited substantial correlation with AFP, Histologic grade, pathologic stage, Residual tumor, and Vascular invasion in HCC. Higher LARS1 expression in HCC was linked to lower progression-free survival (PFS), disease-specific survival (DSS), and overall survival (OS). According to the GO/KEGG study, the important biological process (neutral lipid metabolic process), cellular component (triglyceride-rich plasma lipoprotein), molecular functions (lipase inhibitor activity), and KEGG pathway (cholesterol metabolism) could be a probable function mechanism in promoting HCC. Various pathways as per GSEA revealed that they were enriched in samples with elevated LARS1 expression. The expression level of LARS1 in malignant tumor cells after immunotherapy was significantly higher than that before immunotherapy. LARS1 was also remarkably linked to the infiltration level and the immunomodulators. Conclusion: LARS1 can be used as a biomarker of HCC, which is associated to immune infiltration of HCC. Keywords: hepatocellular carcinoma, leucyl-tRNA synthetase 1, bioinformatics analysis, biomarker, the cancer genome atlas Hepatocellular carcinoma (HCC) represents 75% of all malignancies affecting the liver, 1 making it the eighth most prevalent and third major cause of cancer death. 2 The overall prognosis of hepatocellular carcinoma has improved with the advent of the targeting and immunology era, but its 5-year overall survival rate remains low, particularly for patients with advanced hepatocellular carcinoma. 3,4 There is an urgent need for new targets in current clinical studies to better predict the overall prognosis of patients. We are aware that the tumor microenvironment (TME) is a sophisticated ecosystem that is crucial to the growth and spread of cancer. 5 Immune cells like macrophages and immune cells infiltrate and proliferate, respectively in the TME. Additionally, angiogenesis is induced in TME, and TME is reportedly strongly linked to the development, survival, and metastasis of tumor tissues. 6 The tumor microenvironment of liver cancer is often immunosuppressive, resulting in immune escape and resistance to immunotherapy. Immune checkpoint inhibitors (ICIS) can transform the tumor immune microenvironment from cancer-promoting to anti-cancer by targeting inhibitory immune receptor signals. 7 Tumor immunotherapy has greatly changed the clinical treatment of HCC, immunotherapy approaches are increasingly focused on cytotoxic T lymphocyte-associated protein 4 (CTLA-4) and apoptotic process protein 1(PD-1) monoclonal antibody, because these antibodies lock into the immune checkpoint inhibition pathway. 8 An immunomodulator is a substance that helps the body respond to disease by regulating and controlling the immune system. Immunomodulators includes immunoinhibitors and immunostimulators, More and more studies had shown that different immune phenotypes in solid tumors are closely related to gene types. 9,10 A Protein-coding -Abstract Truncated-
medicine, general & internal